Lexaria生物科学公司通过提供股份筹集了350万美元,其收益用于研发和业务。 Lexaria Bioscience raised $3.5 million via a share offering, with proceeds for R&D and operations.

Lexaria生物科学公司宣布直接提供350万美元,共计266万股,每股1315美元,预计2025年12月16日结算。 Lexaria Bioscience Corp. announced a $3.5 million registered direct offering of 2.66 million shares at $1.315 each, with closing expected December 16, 2025. 公司同时还发行了未注册的股票,每股价格为1.19美元,可立即行使,有效期为5年. Concurrently, it issued unregistered warrants for up to the same number of shares at $1.19 each, exercisable immediately and valid for five years. 收益将为研发、周转资金和公司目的供资。 Proceeds will fund R&D, working capital, and corporate purposes. 这项提议由H.C. Wainwright & Co.管理,在2025年1月生效的交存登记下提出。 The offering is under a shelf registration effective January 2025, managed by H.C. Wainwright & Co. 拥有DehidaTECHTM药品交付平台的公司强调,证券没有完全登记,不能毫无例外地出售。 The company, which owns the DehydraTECH™ drug delivery platform, emphasized that securities are not fully registered and may not be sold without exemptions. 前瞻性说明包括风险。 Forward-looking statements include risks.